

Methotrexate Induced Hepatotoxicity and its Management

Shalini Kumari

Department of Pharmacology, CT Institute of Pharmaceutical Sciences, Jalandhar (Pb) India

Abstract: Liver dysfunction is a major health problem that challenges not only health care professionals but also the pharmaceutical industry and drug regulatory agencies. Commonly used drugs such as anti cancer drugs, certain antibiotics, antitubercular agents, paracetamol and various other toxic chemicals such as carbon tetrachloride (CCL₄), thioacetamide (TAA), excessive alcohol consumption, arsenic and microbes reported to cause hepatotoxicity. In addition to this, genetics, metabolism and immunology also played important role in hepatotoxicity. Methotrexate is commonly used as anticancer and immunosuppressant drug. Its major side effects are bone marrow depression and hepatotoxicity. In the present review, we discuss about the mechanism of methotrexate induced hepatotoxicity and its herbal based treatment. Mechanism of methotrexate induced hepatotoxicity includes oxidative stress which increase the generation of reactive oxygen (ROS) and nitrogen species, inhibits cytosolic NADP-dependent dehydrogenase and NADP malic enzyme, which reduce the levels of glutathion, superoxide dismutase, catalase and ultimately reducing the effectivity of the antioxidant defence system protecting the cell against ROS. Herbal medicines may serve as a vital source of potentially useful for the development of effective therapy to combat a variety of liver problems. Developing a satisfactory herbal therapy to treat severe liver diseases requires systematic investigation of properties like anti-hepatotoxicity and stimulation of liver regeneration.

Keywords: Hepatotoxicity; Methotrexate; Mechanism; Hepatoprotective Plants

1. Introduction

Liver is considered to be one of the most vital organs that functions as a centre of metabolism for nutrients such as proteins, carbohydrates and lipids with excretion of waste metabolites. It also carries out the metabolism, fight against disease, nutrient supply, energy provision and excretion of drugs and other xenobiotics from the body thereby providing protection against foreign substances by detoxifying and eliminating them [1]. As we know that, liver can metabolizes xenobiotics which can leads to the drug-induced liver injury (DILI) and is a potential complication of many drugs. DILI broadly classified into two types: intrinsic and idiosyncratic types; intrinsic DILI generally is dose-dependent and predictable (eg, acetaminophen toxicity), whereas idiosyncratic DILI is unpredictable and does not depend directly on dose [2]. Liver injury is a major health problem that challenges not only health care professionals but also the pharmaceutical industry and drug regulatory agencies [3]. The rate of hepatotoxicity has been reported to be much higher in developing countries like India (8% - 30%) compared to that in advanced countries (2% - 3%) with a similar dose schedule [4]. Drug induced liver injury is one of the main reason of withdrawal of many drugs from the market and most of the time severe case of liver dysfunction required liver transplant or some time death [5]. Mechanism of hepatotoxicity can be investigated through mitochondrial dysfunction and DNA damage [6]. This imperial function caused by drug itself or its cytochrome P450 mediated metabolite. Recent reports on hepatotoxicity suggest that suggest that oxidative stress, microvascular steatosis, imbalance energy storage are major outcome of mitochondrial dysfunction [7].

2. Risk Factors of Hepatotoxicity

Different risk factors which lead to hepatotoxicity like genetic, non genetic or environmental etc [8]. In addition to

this, there are number of drugs whose metabolites leads to liver injury i.e. anticancer drug, antiretroviral drug, alcohol and certain health condition such as age, sex, and diseases eg. TB, HIV are coupled with each other. Some recent research on hepatic injury shown that the risk of hepatotoxicity is increased in various diseased conditions like HIV, diabetic or tuberculosis, cancerous patients [9].

A. Genetic factors

Drug-induced liver injuries (DILI) with different genetic traits and studies conducted till date are hypothesis-driven only. Genetic variations in thioredoxin reductase 1 gene leads to DILI. Moreover, changes in the activity of drug metabolizing phase - I enzyme such as CYP3A, CYP2C9 and CYP2C19 lead to pathogenesis of DILI [10].

In addition to this polymorphism of bioactivities pathway through phase II enzyme i.e. CYP450, detoxification reactions and excretion/transport reaction together with immunological factors i.e. HLA class II antigen, cytokines are major genetic factors which can leads to hepatotoxicity [11].

B. Non-genetic factors

Different environmental and others host factors like age, drug dose, gender, alcohol abuse and some disease condition like cancer, HIV also associate with hepatotoxicity. Age is an important risk factor for hepatotoxicity such as use of aspirin in younger age increase risk to liver injury. Women and men have different susceptibility for drug induced hepatotoxicity. For example according to Hyman and Zimmerman in 1978 women are more susceptible for drugs like isoniazid, nitrofurantoin, chlorpromazine etc where as men are mostly affected azathioprine induced hepatotoxicity [9]. Obesity is also responsible for liver injury. Acute and chronic alcohol consumption is also one of the important causes of liver injury. Some disease condition like HIV tuberculosis, Hepatitis B and C associate disease always increase of liver injury [12].

Volume 5 Issue 9, September 2016

www.ijsr.net

Licensed Under Creative Commons Attribution CC BY




Figure 1: Non genetic factors that involved in hepatotoxicity

3. Methotrexate Induced Hepatotoxicity

Methotrexate is a folic acid antagonist, widely used as a chemotherapeutic agent in the treatment of various cancerous stages such as acute lymphoblastic leukaemia and in the treatment of various inflammatory diseases [13]. It is also used for the treatment of multiple sclerosis, dermatomyositis, sarcoidosis, psoriasis, and rheumatoid arthritis, disorders causing inflammation. Its side effects include hypersensitivity pneumonia, central and peripheral nervous system toxicity, liver and gastrointestinal system dysfunctions, and hematologic failure [14]. MTX exerts its primary toxic effects against the rapidly replicating cells of the bone marrow and gastrointestinal epithelium producing leucopenia and thrombocytopenia. Both low and high-dose therapy can cause hepatotoxicity. Methotrexate at very low dosage affects the liver and causes changes in histology of liver. Other frequently reported adverse toxic effects are malaise, nausea, vomiting, diarrhoea, headache, mild alopecia and fever. Low dose therapy produces a different type of hepatotoxicity which includes cirrhosis. Long term administration of the same causes anaemia. Kidney damage is a frequent complication of high-dose therapy. High-dose therapy results in elevated liver enzymes. However, the use of high-dose methotrexate (as in leukaemia) or prolonged use may result in hepatotoxicity that may lead to progressive fibrosis and cirrhosis. Methotrexate seems to be hepatotoxic, nephrotoxic and toxic to respiratory and reproductive system at very low doses for continuous therapy [15]. On the other hand, substantial evidence supports the concept that MTX was mutagenic and carcinogenic in animals, and the efficacy of this compound is often limited by its severe hepatotoxicity [16]. Toxic side effects of methotrexate have been demonstrated in various animals including rat, mice, rabbit and dog. Clinically, hepatotoxicity, which occurs in long-term use of methotrexate, remains one of the significant restrictions on its use in the doses desired. The inhibition of tetrahydrofolate formation is responsible for both the therapeutic and toxic effects of methotrexate. Although these deleterious toxic effects of methotrexate can theoretically be

reduced or prevented with the addition of folic acid to the treatment. On the contrary, there are studies showing that with the addition of folic acid, the therapeutic effectiveness of methotrexate decreases [17]. MTX induced toxicity appears to be a consequence of the interaction of many factors that includes the dosing schedule, length of treatment, patient risk factors, type of disease, and the presence of genetic and molecular apoptotic factors.

4. Mechanism of Methotrexate Induced Hepatotoxicity

MTX has been shown to lead to a reduction in methionine synthesis, antioxidant enzymes such as catalase, glutathione peroxidase, superoxide dismutase and a decrease of SAM (S-adenosyl methionine) in cerebrospinal fluid of patients on MTX treatment. Due to its antioxidant effects, a deficiency of SAM caused by MTX may be a reason for increased reactive oxygen species (ROS). Effects of MTX are partly due to its direct toxicity by increasing ROS production. Altered balance between ROS production and antioxidant defenses leads to the "oxidative stress" and could be lead to various pathological conditions [13]. The mechanisms of MTX hepatotoxicity could be related to the cellular pathway of the drug [18]. Methotrexate enters the stellate cell bound to folate transporter 1 and is pumped out by the ATP-binding cassette (ABC) family of transporters. Methotrexate is retained within the cell as a polyglutamate that inhibits dihydrofolate reductase (DHFR) and thymidylate synthase (TS) and AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) transformylase, leading to impaired pyrimidine and purine synthesis.

Moreover, methotrexate indirectly affects MTHFR (methylene-tetrahydro folate reductase) and hence the generation of methionine from homocysteine. Excess homocysteine can generate oxidative stress or sensitize the cell to its cytotoxic effects. Homocysteine has been shown to induce endoplasmic reticulum (ER) stress, which when unresolved, leads to fatty infiltration of the liver. In addition to this, it can also activate proinflammatory cytokines. The combination of these insults could contribute to the activation of hepatic stellate cells, which leads to liver fibrosis [19, 20]. Lipid peroxidation plays an essential role in damage to the cell membrane through reactive oxygen radicals. In experimental studies, MTX toxicity has been shown to increase malondialdehyde (MDA), an important index of lipid peroxidation, and this increase has been shown to be suppressed by antioxidant therapies [21, 22]. So it consider a good marker of free radical mediated damage and oxidative stress. This blocking in the synthesis of nucleic acids, certain amino acids and consequently proteins might lead to damage of organelles and plasma membranes of the hepatic parenchymal cells, interfering with their function and allowing leakage of enzymes. Studies have demonstrated that various anti-oxidants are protective against methotrexate hepatotoxicity [23].




Figure 2: Mechanism Of Mtx Induced Hepatotoxicity related to cellular Pathway; MTHFR:Methylenetetrahydro folate reductase, AICAR:5-aminoimidazole-4-caboxamide ribonucleotide, DHFR: dihydrofolate reductase; TS: thymidylate synthetase ; ABC:ATP-binding cassette; MDA: Malondialdehyde;

5. Herbal treatment for methotrexate induced hepatotoxicity

A lot of medicinal plants, traditionally used for thousands of years are present in group of herbal preparation of the Indian traditional health care system. In India, millions of polyherbal commercial formulations reputed to have hepatoprotective action are being used. Scrutiny of the literature indicates that 160 phyto-constituents from 101 plant families have antihepatotoxic activity. Silymarin; a phytoconstituent from (*Silybum Marianum*) has been widely used from ancient times because of its excellent hepatoprotective action [24]. Clinical research has also shown that herbals have genuine

utility in the treatment of liver diseases [1]. There are many herbs, which have been proven to be as hepatoprotective agents while many more are claimed to be hepatoprotective but lack any such scientific evidence to support such claims. Developing a satisfactory herbal therapy to treat severe liver diseases requires systematic investigation of properties like anti-hepatotoxicity (antioxidants), stimulation of liver regeneration. Formulation of herbal drugs with standards of safety and efficacy can revitalize treatment of liver disorders [25]. There are some of the plants which have hepatoprotective activity against methotrexate induced hepatotoxicity.

Table 1: List of plants used as Hepatoprotective

Biological Name	Common Name	Family	Dose Of MTX	Animal Used	Reference
<i>Curcuma longa</i>	Turmeric	Zingiberaceae	20mg/kg/ip/single dose	Albino rats	[16]
<i>Flacourtia indica</i>	Batoka plum	Flacourtiaceae	1750mg/kg/1 days	Albino Mice	[26]
<i>Thymus vulgaris</i>	Thyme	Lamiacea	20mg/kg/ip/3 days	Rabbits	272222 [27]
<i>Silybum marianum</i>	Milk thistle	Compositae	100µg/kg/45 days	Wistar rats	[28]
<i>Camellia sinensis</i>	Green tea	Theaceae	20mg/kg/single dose	Sprague-dawley rats	[29]
<i>Olea europea</i>	Olive	Oleaceae	20mg/kg/12 days	Wistar rats	[30]
<i>Spinach oleracea</i>	Spinach	Chenopodiac	20mg/kg/5 days	Wistar rats	[31]
<i>Vitis vinifera L</i>	Grape	Vitaceae	20mg/kg/single dose	Wistar rats	[32]
<i>Opuntia ficus-indica</i>	Cactus	Cactaceae	20mg/kg/10days	Wistar rats	[33]
<i>Arachis hypogaea</i>	Peanuts	Fabaceae	20mg/kg/5days	Wistar rats	[34]
<i>Passiflora coerulea</i>	Chrysin	Passifloraceae	20mg/kg/7days	Wistar rats	[35]
<i>Prunus armeniaca</i>	apricot	Rosaceae	20mg/kg/10days	Wistar rats	[36]

References

- [1] S.D. Roy, S.Das, D. Shil, K.N. Dutta, "Herbal Hepatoprotective Agents: A Review," *World J PHARM RES*, vol.1(2), pp. 87-89, 2012.
- [2] N.Chalasanani and E. Björnsson, "Risk Factors for Idiosyncratic Drug-Induced Liver Injury," *Gastroenterology*, vol. 138(7), pp. 2246-2259, 2010.
- [3] S.T.S. Mohamed, A.J.M. Christina, N. Chidambaranathan, Ravi V, Gauthaman K, "Hepatoprotective activity of *Annona squamosa* Linn. On experimental animal model," *Int J App Res Nat Products*, vol. 1(3), pp. 1-7, 2008.
- [4] S.K.Sharma, "Antituberculosis drugs and hepatotoxicity" *Infect Genet*, vol.4, pp.167-170, 2004.
- [5] Au JS, Navarro VJ, Rossi S. Review article, "Drug-induced liver injury--its pathophysiology and evolving diagnostic tools," *Aliment Pharmacol Ther*, vol. 34 (1), pp.11-20, 2011.
- [6] B.Fromenty and D.Pessayre, "Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity," *Pharmacol Ther*, vol.67, pp.101-154, 1995.
- [7] G. Labbe, D. Pessayre, B.Fromenty, "Drug-induced liver injury through mitochondrial dysfunction, mechanisms and detection during preclinical safety studies," *Fundam Clin Pharmacol*, vol. 22, pp.335-353, 2008.
- [8] L. DeLeve and N.Kaplowitz, "Prevention and therapy of drug-induced hepatic injury," In: Wolfe M, ed. *Therapy of digestive disorders*. Philadelphia: WB Saunders, Harcourt, Brace, pp.334-48, 2000.
- [9] S.Mishra, V. Aeri and D.P. Katare, "Hepatoprotective medication for liver injury," *World j pharm & pharmaceutical sci*, vol.3(5), pp.891-932, 2014.
- [10] S. Russmann, Y. Barguil, P. Cabalion, M. Kritsanida, D. Duhet, B.H.Lauterburg, "Hepatic injury due to traditional aqueous extracts of kava root in New Caledonia" *Eur J Gastroenterol Hepatol*, vol. 5, pp.1033-1036, 2003.
- [11] R.J. Andrade, M. Robles, E. Ulzurrun, M.I. Lucena, "Drug-induced liver injury, insights from genetic studies," *Pharmacogenomics*, vol.10 (9), pp.1467-87, 2009.
- [12] B. N. Dolores, "Drug-Induced Hepatotoxicity: Metabolic, Genetic and Immunological Basis" *Int. J. Mol. Sci.*, vol.15, pp.6990-7003, 2014.
- [13] C.L Coleshowers, O.O Oguntibeju, M Ukpong & E.J Truter, "Effects of methotrexate on antioxidant enzyme status in a rodent model" *Medical Technology SA*, Vol.24(1), pp.5-9, 2010.
- [14] F. Celik, C. Gocmez, M. Bozkurt, I. Kaplan, K. Kamasak, E. Akil, E. Dogan, A. Guzel, E. Uzar, "Neuroprotective effects of carvacrol and pomegranate against methotrexate induced toxicity in rats," *Eur Rev Med & Pharmacol Sci*, vol.17: pp.2988-2993, 2013.
- [15] N. N. Patel, D. J. Ghodasara, S. Pandey, P. D. Ghodasara, J. H. Khorajiya, B. P. Joshi and C. J. Dave, "Subacute toxicopathological studies of methotrexate in Wistar rats," *Veterinary World*, vol. 7(7), pp.489-495, 2014.
- [16] F. R. A.Ghaffar, I. A.Elaimy, K. A.DougDoug, H. I. Nassar, "Protective and modulatory effects of Curcumin and L-Carnitine against Methotrexate-induced Oxidative stress in albino rats," *Res J Pharm, Bio and Chem Sci*, vol. 4(1), pp.747-754, 2013.
- [17] S.L. Whittle, R.A. Hughes, "Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review," *Rheumatology*, vol.43, pp.267-71, 2004.
- [18] J.M.Kremer, "Toward a better understanding of methotrexate," *Arthritis Rheum*, vol. 50: pp.1370-1382, 2004.
- [19] C. Desouza, M. Keebler, D.B.Namara, V. Fonseca, "Drugs affecting homocysteine metabolism: impact on cardiovascular risk," vol.62, pp.605-616, 2002.
- [20] A. Pandit, T. Sachdeva and P. Bafna, "Drug-Induced Hepatotoxicity: A Review," *J Appl Pharm Sci*, vol. 02 (05), pp. 233-243, 2012.
- [21] A.Cetinkaya, E. Bulbuloglu, E. B. Kurutas and B. Kantarceken, "N-acetylcysteine ameliorates methotrexate induced oxidative liver damage in rats," *Med. Sci. Monit*, vol.12, pp.274-278, 2006.
- [22] N. Jahovic, H.Cevik, A.O. Schirli, B.C.Yegen and G. Sener, "Melatonin prevents methotrexate-induced hepatorenal oxidative injury in rats," *J. Pineal Res*, vol. 34, pp.282-287, 2003.
- [23] B. Ozogula, A. Kisaoglua, M. I. Turanb, D. Altunerc, E. Senerd, N.Cetine, C. Ozturkef, "The effect of mirtazapine on methotrexate-induced toxicity in rat liver," *ScienceAsia*, vol.93, pp.56-362, 2013.
- [24] A.D. Kshirsagar, R. Mohite, A. S. Aggrawal And U.R. Suralkar, "Hepatoprotective Medicinal Plants Of Ayurveda- A Review," *Asian J Pharm Clin Res*, vol.4(3), pp.1-18, 2011.
- [25] A. Shaik, A. Elumalai, M. C. Eswaraiyah, Usha, "An Updated Review on Hepatoprotective Medicinal Plants," *Journal of Drug Delivery & Therapeutics, JDDT*, Vol.2(2), pp.2-3, 2012.
- [26] J. Varkey and J. Thomas, "Protective effect of flacourtia indica (burm.f) merr. In methotrexate induced hepatotoxicity," *PHARMANEST -An Inter J Advances in Pharm Sci*, vol. 2 (2 - 3), pp.115-127, 2011.
- [27] N. H. Swayeh, A. Raghif, B. J. Qasim, H.B. Sahib, "The Protective Effects of Thymus vulgaris Aqueous Extract against Methotrexate-Induced Hepatic Toxicity in Rabbits," *Int. J. Pharm. Sci. Rev. Res*, vol. 29(2) ,pp.187-193, 2014.
- [28] A.R. Ghaffari, H. Noshad, A. Ostadi, M. Ghojzadeh, P. Asadi, "The effects of milk thistle on hepatic fibrosis due to methotrexate in rat," *Hepat Mon*, vol.11(6), pp.464-468, 2011.
- [29] A. H. Jwied, "Hepatoprotective Effect of the Aqueous Extract of *Camellia sinensis* Against Methotrexate-induced Liver Damage in Rats," *Iraqi J Pharm Sci*, vol. 18(2), pp.73-79, 2009.
- [30] Amira O. Abd El-Azim, "Antioxidant effect of olive leaf extract on methotrexate-induced hepatic injury in rats," *canad.J.Clin.Nutr*, vol.01(02), 2014.
- [31] Farah K. Abdul-Wahab & Thukaa Z. Abdul Jalil. study of Iraqi spinach leaves (phytochemical and protective effects against methotrexate-Induced hepatotoxicity in rats). *Iraqi J Pharm Sci*. vol.21(2) PP.8-17, 2012.
- [32] C.Aysun, K.Leylagul, K.Ismail, K.H.Sibel, R. Saraymen, A.Ozturk, S.Ismail and S. Osman, "Role of Grape Seed Extract on Methotrexate Induced Oxidative

- Stress in Rat Liver,” AM J CHIN MED,vol.36(5),pp.861–872,2008.
- [33] A.Akacha,T.Rebai,M.Amri,L.Zourgui, “preventive role of cactus(*opuntia ficus-indica*)cladodes on methotrexate induced biochemical ,haematological and oxidative damage in rats liver,”INT J HOR SCI.
- [34] Tunali-Akbay T, O.Sehirli , F. Ercan ,G. Sener, “Resveratrol protect against MTX induced hepatic injury in rats,”J Pharmacol Pharmaceut Sci ,vol.13(2), pp.303 – 310,2010.
- [35] N.Ali, S.Rashid,S.Nafes,S.K.Hasan, “ Beneficial effects of chrysin against MTX induced hepatotoxicity via attenuation of oxidative stress & apoptosis,”Mol.cell .biochem ,vol.385(1),pp.215-23,2014.
- [36] N.vardi,H.parlarpinar,B.ATES,A.cetin,O.Ali, “The protective effect of *prunus armeniaca* against MTX induced oxidative damage and apoptosis in rats,”J PHY BIOCHEM,vol.69(3),pp.371-381,2013.

